Login to Your Account



FDA approves Jazz Pharma's Vyxeos for 2 types of high-risk AML

By Michael Fitzhugh
Staff Writer

Thursday, August 3, 2017

Jazz Pharmaceuticals plc is seeing the first concrete dividend of its $1.5 billion buyout of Celator Pharmaceuticals Inc. with FDA approval for Vyxeos.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription